Liver HealthNCT07738744
A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Liver and Digestive Health
A study testing Edenboost Alpha Cleanse in people with Liver Health and Digestive Health, run by Edenboost at 1 site in United States.
Trial summary
This study will evaluate the effects of Edenboost Alpha Cleanse, a dietary supplement, on symptoms associated with liver and digestive health. The study is a single-arm, open-label trial in which all 40 enrolled participants will use the test product daily for 12 weeks. Read more about this study
- Who is it for?
- Ages 40 to 65 years
- Conditions the study is for
- Liver Health, Digestive Health, Fatigue
- What is being tested?
- Edenboost Alpha Cleanse
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Nov 2025to 15 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be male or female.
- Be aged 40-65.
- Anyone who has struggled with low energy levels and fatigue over the past four weeks.
- Anyone who has struggled with at least two of the following symptoms over the past four weeks: abdominal bloating, abdominal discomfort, constipation, diarrhea, digestive discomfort.
- Willing to maintain the same diet, sleep pattern, and exercise regimen consistently throughout the study duration.
- If taking any other supplements, medications, or herbal remedies, has been doing so consistently for at least three months and is willing to maintain this routine for the duration of the trial.
- Willing to avoid introducing any other supplements, medications, or herbal remedies for the duration of the trial.
- Resides in the United States.
Who cannot join
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including mental health disorders, a history of serious illness in the last three months, a history of substance abuse, or planned surgery during the study period.
- Anyone with a known history of severe digestive disorders like acid reflux, peptic ulcers, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), GI bleeding, Crohn's disease, Ulcerative Colitis (UC), or gastrointestinal tract surgeries.
- Anyone with a history of kidney stones.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- Anyone on Coumadin (warfarin) or antiplatelet therapy (e.g., Plavix (clopidogrel), aspirin).
Show all 10Show fewer
- Anyone with uncontrolled chronic disease, including but not limited to diabetes, hypertension (high blood pressure), and thyroid-related conditions.
- Anyone unwilling to follow the study protocol.
- Anyone who is currently a smoker or has been a smoker in the past 3 months.
- Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration.
Trial locations and contacts
1 site in 1 country.
About this study
This study will evaluate the effects of Edenboost Alpha Cleanse, a dietary supplement, on symptoms associated with liver and digestive health. The study is a single-arm, open-label trial in which all 40 enrolled participants will use the test product daily for 12 weeks.
Participants will complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and will undergo blood testing (hepatic function panel) at Baseline and Week 12. Primary outcomes focus on changes in liver function biomarkers, while secondary outcomes capture participants' self-reported experiences of energy levels, abdominal bloating, abdominal pain, fatigue, and nausea.
- Conditions
- Liver Health, Digestive Health, Fatigue, Abdominal Bloating, Abdominal Pain, Nausea
- Being tested
- Edenboost Alpha Cleanse
- Medical subject headings
- Fatigue, Abdominal Pain, Nausea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Edenboost Alpha CleanseDietary supplement
All participants receive Edenboost Alpha Cleanse (two capsules once daily with the first meal of the day) for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Edenboost Alpha Cleanse | Experimental | Not described Receives: Dietary Supplement: Edenboost Alpha Cleanse |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Alanine Aminotransferase (ALT/SGPT)
Change in serum ALT/SGPT level assessed via hepatic function panel blood test at Labcorp
Measured: Baseline and Week 12
Change in Albumin
Change in serum albumin level assessed via hepatic function panel blood test at Labcorp
Measured: Baseline and Week 12
Change in Alkaline Phosphatase
Change in serum alkaline phosphatase level assessed via hepatic function panel blood test at Labcorp
Measured: Baseline and Week 12
Change in Aspartate Aminotransferase (AST/SGOT)
Change in serum AST/SGOT level assessed via hepatic function panel blood test at Labcorp
Measured: Baseline and Week 12
Change in Bilirubin
Change in serum bilirubin level assessed via hepatic function panel blood test at Labcorp
Measured: Baseline and Week 12
Change in Total Protein
Change in serum total protein level assessed via hepatic function panel blood test at Labcorp
Measured: Baseline and Week 12
Secondary outcomes (5)
Change in Self-Reported Abdominal Bloating
Participant-reported change in abdominal bloating assessed via self-reported questionnaire
Measured: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Abdominal Pain
Participant-reported change in abdominal pain assessed via self-reported questionnaire
Measured: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Fatigue
Participant-reported change in fatigue assessed via self-reported questionnaire
Measured: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Nausea
Participant-reported change in nausea assessed via self-reported questionnaire
Measured: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Energy Levels
Participant-reported change in energy levels assessed via self-reported questionnaire
Measured: Baseline, Week 4, Week 8, and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study start17 Nov 2025
- Primary completion15 Jan 2026
- Study completion15 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver HealthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Edenboost
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07738744
- Sponsor's protocol ID
- 20820
- Other IDs
- legacy-20820
- Status last verified
- Jul 2026
- First submitted
- 28 Jul 2026
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Liver and Digestive Health
- ClinicalTrials.gov ID
- NCT07738744
- Acronym / sponsor ID
- 20820
- Conditions
- Liver Health, Digestive Health, Fatigue, Abdominal Bloating, Abdominal Pain, Nausea
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- EdenboostIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 17 Nov 2025 (actual)
- Primary completion
- 15 Jan 2026 (actual)
- Study completion
- 15 Jan 2026 (actual)
- First posted
- 31 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the effects of Edenboost Alpha Cleanse, a dietary supplement, on symptoms associated with liver and digestive health. The study is a single-arm, open-label trial in which all 40 enrolled participants will use the test product daily for 12 weeks.
Participants will complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and will undergo blood testing (hepatic function panel) at Baseline and Week 12. Primary outcomes focus on changes in liver function biomarkers, while secondary outcomes capture participants' self-reported experiences of energy levels, abdominal bloating, abdominal pain, fatigue, and nausea.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Edenboost Alpha Cleanse | Experimental | Dietary Supplement: Edenboost Alpha Cleanse |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Be male or female.
- Be aged 40-65.
- Anyone who has struggled with low energy levels and fatigue over the past four weeks.
- Anyone who has struggled with at least two of the following symptoms over the past four weeks: abdominal bloating, abdominal discomfort, constipation, diarrhea, digestive discomfort.
- Willing to maintain the same diet, sleep pattern, and exercise regimen consistently throughout the study duration.
Key exclusion criteria (10 listed)
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including mental health disorders, a history of serious illness in the last three months, a history of substance abuse, or planned surgery during the study period.
- Anyone with a known history of severe digestive disorders like acid reflux, peptic ulcers, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), GI bleeding, Crohn's disease, Ulcerative Colitis (UC), or gastrointestinal tract surgeries.
- Anyone with a history of kidney stones.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Edenboost Alpha CleanseAll participants receive Edenboost Alpha Cleanse (two capsules once daily with the first meal of the day) for 12 weeks. | Dietary supplement | Edenboost Alpha Cleanse |
Primary outcome
Change in Alanine Aminotransferase (ALT/SGPT)
Time frame: Baseline and Week 12
Change in serum ALT/SGPT level assessed via hepatic function panel blood test at Labcorp
Change in Albumin
Time frame: Baseline and Week 12
Change in serum albumin level assessed via hepatic function panel blood test at Labcorp
Change in Alkaline Phosphatase
Time frame: Baseline and Week 12
Change in serum alkaline phosphatase level assessed via hepatic function panel blood test at Labcorp
Change in Aspartate Aminotransferase (AST/SGOT)
Time frame: Baseline and Week 12
Change in serum AST/SGOT level assessed via hepatic function panel blood test at Labcorp
Change in Bilirubin
Time frame: Baseline and Week 12
Change in serum bilirubin level assessed via hepatic function panel blood test at Labcorp
Change in Total Protein
Time frame: Baseline and Week 12
Change in serum total protein level assessed via hepatic function panel blood test at Labcorp
5 secondary outcomes
Change in Self-Reported Abdominal Bloating
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Abdominal Pain
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Fatigue
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Nausea
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Energy Levels
Time frame: Baseline, Week 4, Week 8, and Week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
Related trials for Liver Health
Recruiting
Dietary Intervention Study on Liver Health in Young Adults
Liver Health
Recruiting
NAFLD Clinical Care Pathway
NAFLD, MASLD
Recruiting
Multidisciplinary Non-Pharmacological Intervention to Improve Quality of Life in Solid Organ Transplant Recipients
Heart Transplant Patients, Kidney Transplant Patients
Active, not recruiting
Online Prehabilitation for Patients Awaiting Liver Transplantation
Cirrhosis, Liver, Liver Transplant Surgery
Recruiting
In-situ vs Ex-situ Liver Preservation
Liver Disease (Alcoholic or Not), Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Edenboost Alpha Cleanse in people with Liver Health and Digestive Health, run by Edenboost at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Alanine Aminotransferase (ALT/SGPT) (time frame: Baseline and Week 12). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.